We are live on ! Find out more
OPRX icon

OptimizeRx

92 hedge funds and large institutions have $131M invested in OptimizeRx in 2024 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 24 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

222% more call options, than puts

Call options by funds: $1.76M | Put options by funds: $548K

63% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 24

1.18% more ownership

Funds ownership: 70.42%71.6% (+1.2%)

5% less funds holding

Funds holding: 9792 (-5)

16% less capital invested

Capital invested by funds: $155M → $131M (-$24.5M)

18% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 22

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
92
Holders Change
-5
Holders Change %
-5.15%
% of All Funds
1.33%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
18
Increased
39
Reduced
24
Closed
22
Calls
$1.76M
Puts
$548K
Net Calls
+$1.21M
Net Calls Change
+$998K
Name Holding Trade Value Shares
Change
Change in
Stake
FLAM
1
First Light Asset Management
Minnesota
$18.3M +$982K +89,377 +5%
DSCM
2
Divisadero Street Capital Management
Florida
$13.2M -$2.82M -256,987 -16%
BlackRock
3
BlackRock
New York
$11.8M +$990K +90,127 +8%
AIC
4
AWM Investment Company
New York
$10M +$1.64M +149,322 +18%
Vanguard Group
5
Vanguard Group
Pennsylvania
$9.74M -$590K -53,725 -5%
SM
6
Samjo Management
New York
$7.8M +$2.35M +214,062 +38%
William Blair & Company
7
William Blair & Company
Illinois
$6.44M -$1.52M -138,816 -18%
RHJA
8
Rice Hall James & Associates
California
$4.96M +$1.04M +94,253 +23%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$4.16M +$331K +30,088 +8%
GIPM
10
G2 Investment Partners Management
New York
$3.92M +$211K +19,211 +5%
State Street
11
State Street
Massachusetts
$3.48M +$148K +13,443 +4%
KCM
12
Kennedy Capital Management
Missouri
$3.34M +$158K +14,398 +5%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$3.24M +$395K +35,957 +12%
UBS AM
14
UBS AM
Illinois
$3.1M +$3.41M +310,000 New
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$3.08M -$446K -40,558 -12%
EIM
16
Essex Investment Management
Massachusetts
$1.69M +$908K +82,697 +95%
BCM
17
Bridgeway Capital Management
Texas
$1.54M +$473K +43,100 +39%
Northern Trust
18
Northern Trust
Illinois
$1.46M -$75.6K -6,881 -4%
Renaissance Technologies
19
Renaissance Technologies
New York
$1.42M +$788K +71,700 +102%
BAM
20
Bullseye Asset Management
Colorado
$1.38M +$165K +15,000 +12%
JP Morgan Chase
21
JP Morgan Chase
New York
$1.13M -$291K -26,515 -19%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$1.12M +$110K +10,041 +10%
BFM
23
Boothbay Fund Management
New York
$1.05M +$164K +14,916 +16%
Citadel Advisors
24
Citadel Advisors
Florida
$1.02M +$552K +50,252 +96%
PCM
25
Perkins Capital Management
Minnesota
$1.02M -$34.1K -3,100 -3%

OPRX Hedge Fund Activity: Q2 2024 in Review

92 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q2 2024, worth a combined $131M — down 16% from $155M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of OPRX and 18 opened new positions — a net loss of 4 holders — while 24 trimmed existing stakes and 39 added.

The largest buyer was UBS AM, opening a new position worth an estimated $3.41M. The largest seller was Divisadero Street Capital Management, cutting an estimated $2.82M.

  • 92 institutional investors held OptimizeRx (OPRX) as of Q2 2024, down from 97 in Q1 2024.
  • Funds reported $131M of OptimizeRx stock for Q2 2024, down 16% quarter-over-quarter.
  • 18 funds opened new OptimizeRx positions in Q2 2024 and 22 closed out, a net change of -4 holders.
  • The largest OptimizeRx buyer in Q2 2024 was UBS AM, an estimated $3.41M added.
  • The largest OptimizeRx seller in Q2 2024 was Divisadero Street Capital Management, an estimated $2.82M sold.

Based on aggregated 13F filings for Q2 2024.